Brentuximab Vedotin Combo Elicits Responses in Advanced Classical Hodgkin Lymphoma
December 11th 2023
Brentuximab vedotin plus nivolumab, doxorubicin, and dacarbazine was found to have efficacy and acceptable safety and tolerability when used as a frontline treatment in patients with previously untreated advanced, classical Hodgkin lymphoma.